Jeffrey M. Spier, MD

Articles by Jeffrey M. Spier, MD

Q&A: Jeffrey Spier, MD, on ARPI fatigue and the case for dose reduction

October 21st 2026

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide

ByJeffrey M. Spier, MD

October 19th 2026

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Managing ARPI-related fatigue: Balancing tolerability and treatment persistence

ByJeffrey M. Spier, MD

October 19th 2026

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.